| 51.89 0.31 (0.6%) | 06-12 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 63.78 | 1-year : | 69.92 |
| Resists | First : | 54.6 | Second : | 59.86 |
| Pivot price | 49.89  |
|||
| Supports | First : | 46.09 | Second : | 38.35 |
| MAs | MA(5) : | 50.09 |
MA(20) : | 50.99 |
| MA(100) : | 47.96 |
MA(250) : | 40.86 |
|
| MACD | MACD : | -0.7 |
Signal : | -0.7 |
| %K %D | K(14,3) : | 52.7 |
D(3) : | 41 |
| RSI | RSI(14): 53.6 |
|||
| 52-week | High : | 59.86 | Low : | 26.27 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ KNSA ] has closed below upper band by 23.8%. Bollinger Bands are 11% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 52.54 - 52.75 | 52.75 - 52.95 |
| Low: | 50.84 - 51.08 | 51.08 - 51.32 |
| Close: | 51.5 - 51.87 | 51.87 - 52.24 |
Kiniksa Pharmaceuticals, Ltd. is a global biopharmaceutical firm dedicated to discovering, acquiring, advancing, and commercializing medical therapies for individuals suffering from severe illnesses where current treatment options are insufficient. Its pipeline of potential treatments includes ARCALYST, an interleukin-1alpha and interleukin-1beta inhibitor, aimed at addressing recurrent pericarditis, an inflammatory heart condition. Also in development is Mavrilimumab, a monoclonal antibody inhibitor that has successfully concluded Phase II clinical trials for managing giant cell arteritis. Additionally, Vixarelimab, another monoclonal antibody, is currently undergoing Phase 2a clinical trials as a potential therapy for prurigo nodularis, a persistent inflammatory skin disorder. The company's pipeline further includes KPL-404, a monoclonal antibody engineered to inhibit the CD40-CD154 interaction, which plays a crucial role in T-cell co-stimulation, B-cell development, immunoglobulin class switching, and the body's type 1 immune response. Established in 2015, Kiniksa Pharmaceuticals, Ltd. operates from its headquarters in Hamilton, Bermuda.
Sat, 13 Jun 2026
Castleark Management LLC Raises Stock Holdings in Kiniksa Pharmaceuticals International, plc $KNSA - MarketBeat
Mon, 08 Jun 2026
Kiniksa Pharmaceuticals, Ltd. - MLQ.ai
Tue, 02 Jun 2026
Kiniksa (NASDAQ: KNSA) director exercises 2,799 RSUs and gets options on 12,158 shares - Stock Titan
Tue, 02 Jun 2026
Kiniksa (KNSA) director exercises RSUs and receives new option grant - Stock Titan
Tue, 02 Jun 2026
Kiniksa Pharmaceuticals, Ltd. - MLQ.ai
Fri, 29 May 2026
Kiniksa schedules June investor fireside chats with Jefferies and Goldman Sachs - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 46 (M) |
| Shares Float | 39 (M) |
| Held by Insiders | 3.5 (%) |
| Held by Institutions | 102.7 (%) |
| Shares Short | 3,040 (K) |
| Shares Short P.Month | 3,530 (K) |
| EPS | 0.91 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 8.22 |
| Profit Margin | 9.6 % |
| Operating Margin | 13.6 % |
| Return on Assets (ttm) | 8.1 % |
| Return on Equity (ttm) | 13.7 % |
| Qtrly Rev. Growth | 55.5 % |
| Gross Profit (p.s.) | 8.9 |
| Sales Per Share | 16.28 |
| EBITDA (p.s.) | 2.04 |
| Qtrly Earnings Growth | 145.5 % |
| Operating Cash Flow | 166 (M) |
| Levered Free Cash Flow | 118 (M) |
| PE Ratio | 57.02 |
| PEG Ratio | 0 |
| Price to Book value | 6.31 |
| Price to Sales | 3.18 |
| Price to Cash Flow | 14.48 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|